WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) will announce today at the Cowen and Company 28th Annual Health Care Conference results from its initial meeting with the U.S. Food & Drug Administration (FDA) regarding the development of its lead JAK inhibitor, INCB18424, for myelofibrosis.
